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Nanobodies are single domain antibodies derived from llama heavy-chain only antibodies
(HCAbs). They represent a new generation of biologicals with unique properties:
nanobodies show excellent tissue distribution, high temperature and pH stability, are easy
to produce recombinantly and can readily be converted into different formats such as
Fc-fusion proteins or hetero-dimers. Moreover, nanobodies have the unique ability to bind
molecular clefts, such as the active site of enzymes, thereby interfering with the function
of the target protein. Over the last decade, numerous nanobodies have been developed
against proteins involved in inflammation with the aim to modulate their immune functions.
Here, we give an overview about recently developed nanobodies that target immunological
pathways linked to neuroinflammation. Furthermore, we highlight strategies to modify
nanobodies so that they can overcome the blood brain barrier and serve as highly specific
therapeutics for acute inflammatory brain injury.
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FROM LLAMA HEAVY-CHAIN-ONLY ANTIBODIES TO SINGLE
DOMAIN NANOBODIES
Mammalian immunoglobulins are composed of two heavy and
two light chains which together form the antigen-binding
paratope. In 1993, the group of Raymond Hamers demon-
strated the existence of a new type of immunoglobulin in the
serum of camels (Camelus dromedarius). These antibodies consist
of heavy-chain dimers devoid of light chains, which brought
them the name “heavy-chain-only antibodies” (HCAbs; Hamers-
Casterman et al., 1993). These HCAbs are present in all mem-
bers of the camelid family and account for 30 to 75% of
circulating immunoglobulins (Hamers-Casterman et al., 1993;
Sundberg and Mariuzza, 2002; Blanc et al., 2009; Muyldermans,
2013).
Structurally, the heavy-chains of HCAbs are composed of the
antigen-binding variable domain (VHH) followed by a hinge
region and two constant domains (CH2 and CH3), whereas the
CH1 domain known from conventional antibodies is missing
(Figure 1A; Hamers-Casterman et al., 1993). Apart from their
unusual architecture, HCAbs also differ from conventional anti-
bodies in their antigen recognition: VH and VL of conventional
antibodies usually form a concave or flat shaped paratope suited
for the binding of small molecules, peptides, or large antigens
(Sundberg and Mariuzza, 2002; Blanc et al., 2009; Muyldermans,
2013). The paratope formed by a VHH domain, however, shows
a convex shape and, therefore, enables the binding to molecular
cavities or clefts, e.g., the active site of enzymes. Many enzyme-
specific VHH domains thereby act as antagonists (Figure 1B).
This unique feature could be attributed to the long comple-
mentarity determining region 3 (CDR3) of the VHH domain
which is able to form finger-like extensions (De Genst et al.,
2006).
With approximately 15 kDa VHHs are the smallest nat-
urally occurring antigen-binding protein domains. The name
“nanobodies” was coined to reflect the small size of VHHs as
recombinant proteins (Muyldermans, 2013). In order to generate
nanobodies from HCAbs, llamas are immunized and boosted
with the desired antigen. After the last boost, B cells are collected
from peripheral blood to isolate mRNA, which is transcribed into
cDNA. The gene region encoding for the VHH domain can be
amplified via PCR and cloned into a phagemid vector. This strat-
egy generates phages that express one particular nanobody clone
on their surface and, at the same time, carry the DNA sequence
encoding for this specific nanobody. Applying the phage display
technology finally allows the selection of nanobody clones against
the desired antigen (Clackson et al., 1991). Taken together, this
approach allows the selection of target-specific nanobodies and,
simultaneosly, delivers the DNA sequence coding for the selected
nanobodies which then can be further used for recombinant
expression (Wesolowski et al., 2009).
Most generated nanobodies are stable at high temperatures,
low and high pH, and other stringent conditions (Arbabi
Ghahroudi et al., 1997; Dumoulin et al., 2002). Additionally,
phage display selection can be performed under harsh condi-
tions, e.g., the presence of detergents to improve the selection
of more resistant clones. If applied in vivo, nanobodies display
low toxicity and immunogenicity due to their small size, their
relatively high sequence identity to human VH, and to their rapid
clearance from the periphery via the kidney (Hamers-Casterman
et al., 1993; Muyldermans, 2013). To increase the in vivo half-life
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FIGURE 1 | Nanobodies are single-domain antibodies derived from llama
heavy-chain-only antibodies. (A) Conventional antibodies from mammals
are composed of two heavy- and two light chains, camelidae additionally
express antibodies devoid of ligh chains, so called heavy-chain only
antibodies. (B) Heavy-chain-only antibodies can bind to molecular crevices
thereby blocking the active site of enzymes. (C) Nanobodies derived from
heavy-chain-only antibodies can be engineered as dimers, half-life-extended
heterotrimers containing an anti-albumin nanobody or as dimeric
Fc-fusionprotein. (D) Anti-inflammatory nanobodies are currently evaluated in
clinical trials.
nanobodies can be reformatted (converted into other formats
by genetic engineering), e.g., to homodimers, heterotrimers
containing an anti-serum-albumin nanobody (Sundberg and
Mariuzza, 2002; Coppieters et al., 2006; Tijink et al., 2008; Blanc
et al., 2009; Muyldermans, 2013) or nanobody-Fc-fusion proteins
(Figure 1C). Thereby, nanobodies can be tailored for the desired
in vivo application, e.g., small monomers for short-term in vivo
imaging or half life-extended nanobodies for long-term thera-
peutic treatment (Hamers-Casterman et al., 1993; Hassanzadeh-
Ghassabeh et al., 2013). The potential to antagonize targeted
antigens, the high stability, the low toxicity and the possibility to
tailor them for in vivo applications makes nanobodies a promising
new generation of therapeutic proteins. To date, several anti-
inflammatory nanobodies are in clinical trials (Figure 1D), and
more than 700 persons have received nanobodies in clinical trials
without any adverse off-target side effects (Van Bockstaele et al.,
2009; Williams, 2013).
NANOBODIES AS MODULATORS OF IMMUNE CELLS AND
INFLAMMATION
In order to fight infectious diseases, numerous nanobodies have
been generated against bacterial and viral antigens to prevent or
ameliorate pathogenicity (Sundberg and Mariuzza, 2002; Blanc
et al., 2009; Wesolowski et al., 2009; Muyldermans, 2013). More
recently, key players of immunological pathways have come into
focus as targets for nanobodies in order to modulate immune
responses. This has resulted in the generation of nanobod-
ies directed against Fc-receptors (FcR), chemokine receptors,
chemokines, cytokines, and ecto-enzymes. These nanobodies
often show high target specificities and are able to modulate
the function of their target in an agonistic or antagonistic
fashion.
NANOBODIES DIRECTED AGAINST Fc-RECEPTORS
Fc receptors are expressed on the cell surface of diverse immune
cells and are able to bind the Fc portion of antibodies thereby
conducting either stimulatory or inhibitory signals, depending on
the Fc receptor class (De Genst et al., 2006; Nimmerjahn and
Ravetch, 2007). In 2008, Behar et al. described the isolation of
Fc-γ-RIII-specific nanobodies from a llama immune library
(Behar et al., 2008; Muyldermans, 2013). The selected nanobodies
(C21 and C28) showed specific binding to both, Fc-γ-RIIIB and
Fc-γ-RIIIA, and no binding to Fc-γ-RI or Fc-γ-RII. Binding of
the Fc-part of an antibody to the Fc-γ-RIII on NK cells conducts
an activating signal leading to the release of the proinflammatory
cytokine interferon gamma (IFNγ). Binding of nanobodies C21
and C28 in an agonistic fashion to Fc-γ-RIIIA on human NK cells
induced the expression of IFNγ (Clackson et al., 1991; Behar et al.,
2008). In later studies, these nanobodies were used to generate
Fab-like bispecific antibodies containing one nanobody directed
against the Fc-γ-RIIIA and one directed against the carcinoem-
bryogenic antigen (CEA; Behar et al., 2009; Wesolowski et al.,
2009). By this strategy, the agonistic anti-Fc-γ-RIIIA nanobodies
could be targeted to CEA+-tumor cells where they activate NK
cells in situ inducing the lysis of the tumor cells. Further, injec-
tion of these bispecific constructs reduced the tumor growth in
immunodeficient mice xenografted with CEA+-tumor cells when
co-administered with human peripheral blood mononuclear cells
(PBMCs; Arbabi Ghahroudi et al., 1997; Dumoulin et al., 2002;
Rozan et al., 2013). It has to be evaluated whether FcR targeting
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nanobodies could also be applied as therapeutics for acute brain
injury. A study using Fc-γ-R deficient mice showed a reduced
infarct size compared to WT animals which could be linked to
decreased microglia activation (Komine-Kobayashi et al., 2004).
NANOBODIES DIRECTED AGAINST CHEMOKINE RECEPTORS AND
CHEMOKINES
The generation of functional monoclonal antibodies against G-
protein coupled receptors (GPCRs) such as chemokine recep-
tors is notoriously difficult. With their unique binding features,
nanobodies display a promising alternative for the generation of
functional biologics to modulate chemokine receptor function,
e.g., to inhibit immune cell migration to inflammatory sites.
In 2010, the group of Martine Smit reported the generation of
two nanobodies that specifically target the chemokine receptor
CXCR4 (Jähnichen et al., 2010). Nanobodies 238D2 and 238D4
showed potent competitive inhibition of CXCL12 binding to
CXCR4. When injected into monkeys, anti-CXCR4 nanobodies
induced the mobilization of hematopoetic stem cells by dis-
rupting the CXCR4/CXCL12 axis contributing to the residence
of hematopoetic stem cells in the bone marrow. In 2013, the
same group reported the generation of antagonistic nanobodies
targeting CXCR7. Injected into mice, these nanobodies showed
beneficial effects in an in vivo xenograft model of head and neck
cancer (Maussang et al., 2013). Simultaneously, the same group
published a panel of nanobodies specifically targeting CCL2,
CCL5, CXCL11 and CXCL12. Binding of nanobodies to CXCL11
and CXCL12 inhibited chemokine receptor binding and thereby
preventing chemokine receptor activation induced cell migration
in vitro (Blanchetot et al., 2013). Since diverse chemokines and
their receptors are known to contribute to the migration of
immune cells to the brain after brain damage (Amantea et al.,
2009), the nanobodies described above might be a promising
therapeutic alternative for the treatment of acute brain injury.
NANOBODIES DIRECTED AGAINST CYTOKINES
Targeting and neutralization of proinflammatory cytokines by
monoclonal antibodies is a promising strategy for the treatment
of inflammatory diseases (Kopf et al., 2010). Tumor necrosis
factor α (TNFα) was the first cytokine functionally targeted
by nanobodies (TR2 = anti-human TNFα, MT1 = anti-mouse
TNFα). Expressed as bivalent molecules TR2-TR2 nanobodies
showed a slightly higher neutralizing capacity than the TNFα
neutralizing biologicals infliximab, adalimumab and etanercept
(Coppieters et al., 2006). Further, heterotrimeric nanobod-
ies (MT1-MT1-AR1) consisting of two MT1 and one serum
albumin-binding nanobody (AR1) showed excellent therapeutic
effects in the collagen-induced arthritis mouse model (Coppieters
et al., 2006). Another study evaluating the therapeutic potential
of bivalent TNFα nanobodies in a mouse model of chronic
colitis impressively demonstrated the versatility of the nanobody
technology: genetically engineered Lactococcus lactis secreting
MT1-MT1 bivalent anti-TNFα nanobodies profoundly reduced
gut inflammation when daily administered by gavage (Vanden-
broucke et al., 2010). Apart from neutralizing cytokines nanobod-
ies can be used to “guide” cytokines to their desired target cells.
In a proof-of-concept study Garcin et al. (2014) demonstrated
that the toxicity of type I interferons, when applied in vivo,
could be markedly reduced by genetically engineering fusion
proteins of mutated IFNα2 with lower receptor affinities and
nanobodies targeting programmed cell death 1 ligand 2 (PD-L2;
Garcin et al., 2014). When injected into mice these fusion proteins
preferentially induced IFNα2-mediated STAT1 phosphorylation
in PD-L2 expressing cells in peritoneum and spleen, illustrating
that nanobodies are valuable tools for “activity-by-targeting”
based therapeutic approaches. For the treatment of acute brain
injury, the nanobody-based neutralization of proinflammatory
cytokines such as TNFα could be a promising approach to min-
imize inflammation-related further loss of brain tissue. Con-
versely, it is conceivable that nanobodies could be used to guide
modified anti-inflammatory cytokines such as interleukin-10 to
sites of brain inflammation to suppress inflammatory responses
in situ.
NANOBODIES DIRECTED AGAINST ECTO-ENZYMES
The first cell surface resident ecto-enzyme targeted by nanobod-
ies was murine ADP-ribosyltransferase C2 (ARTC2; Koch-Nolte
et al., 2007; Menzel et al., 2013). ARTC2 is expressed on the
cell surface of T cells and covalently attaches the ADP-ribose
group of its substrate nicotinamide adenin dinucleotide (NAD)
to arginine residues of several cell surface proteins. One well-
characterized target of ARTC2 is the ATP-gated P2X7 ion channel.
ADP-ribosylation of P2X7 on T cells induces channel opening and
influx of calcium ions. Prolonged activation by ADP-ribosylation
causes shedding of cell surface proteins such as CD62L and CD27,
externalization of phosphatidylserin und ultimately cell death
(Seman et al., 2003). Analyses of T cell subpopulations revealed
different sensitivities to NAD-mediated cell death, with regulatory
T cells (Tregs) and natural killer T cells (NKT cells) being highly
susceptible (Hubert et al., 2010; Rissiek et al., 2014b). Antagoniz-
ing ARTC2 with nanobody s+16a prevents ADP-ribosylation of
P2X7 in vitro and in vivo. In a proof-of-principle study Scheuplein
et al. showed that injection of s+16a as Fc-fusion protein restores
an otherwise naturally NAD-depleted NKT cell population in
diabetogenic NOD-CD38ko mice (Scheuplein et al., 2010). When
activated in vivo by injection of α-galactosylceramide, s+16a-
restored NKT cells were capable of inhibiting the development of
type 1 diabetes. A further study showed that injection of s+16a
prevented ARTC2/P2X7 mediated cell death of highly susceptible
Tregs and NKT cells during in vitro assays and adoptive transfer
experiments, revealing the potential of s+16a as valuable tool
for research and as potential therapeutic agent (Rissiek et al.,
2014a). It has been shown that P2X7 activation is detrimental for
the outcome of ischemic stroke (Arbeloa et al., 2012). Further,
genetic deletion of the NAD-degrading ecto-enzyme CD38 in
mice exacerbates ischemic damage (Choe et al., 2011), which
might provide ARTC2 with an increased access to its substrate
NAD. Therefore, s+16a could be used to clarify the role of the
ARTC2/P2X7 axis during acute brain damage.
MODIFYING NANOBODIES TO CROSS THE BLOOD-BRAIN
BARRIER
The therapeutic application of nanobodies has been tested in
diverse mouse models of inflammation. However, therapeutic
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 344 | 3
Rissiek et al. Nanobodies as modulators of brain inflammation
applications of biologics in neuroinflammatory diseases face an
important biological barrier. The obstacle for effective delivery
of therapeutic drugs, especially antibodies, is the blood brain
barrier, which is only permeable for lipophilic molecules of up
to 400 kDa of size (Pardridge, 2012). The delivery of conven-
tional antibodies to the brain is especially tedious because of
Fc-receptor mediated efflux to the blood (Cooper et al., 2013).
Therefore, nanobodies lacking an Fc-part represent a promising
alternative to brain targeting monoclonal antibodies. Indeed, sev-
eral groups have tested different strategies to deploy nanobodies
as brain-drug deliverers or as bonafide brain-targeting drugs
(Figure 2).
Muruganadam et al. described in 2002 the selection of a
nanobody (FC5) that transmigrates across human blood-brain-
barrier endothelium in vitro (Muruganandam et al., 2002). Later,
the same group suggested that FC5 binds a putative α(2,3)-
sialoglycoprotein receptor and is transcytosed via clathrin vesicles
(Abulrob et al., 2005). In a therapeutic experimental setup using
the Hargreaves model of inflammatory pain, it was shown that
FC5 conjugated with opioid peptide Dal could be deployed as
drug delivery shuttle in vivo to induce a significant analgesic
response in contrast to unconjugated Dal peptide (Farrington
et al., 2014). Other approaches utilize receptor-mediated tran-
scytosis for brain targeting. A recently published study showed
that a fusionprotein of a peptide derived from apolipoprotein E
(ApoE) and a model therapeutic protein (α-L-iduronidase) could
be transferred to the brain via binding to the LDL receptor (LRP)
expressed on cells of the blood-brain barrier (Wang et al., 2013).
Furthermore, the transferrin receptor and the insulin receptor
have also been exploited for receptor-mediated transcytosis of
small molecule drugs and therapeutic proteins (Boado et al., 2012;
Xiao and Gan, 2013). These studies indicate that nanobodies
binding these receptors and triggering transcytosis could be a
promising alternative to ligand-based delivery of drugs to the
brain.
A study by Pierre Lafaye’s group (Li et al., 2012) reported
that nanobodies with a high isoelectric point (pI) spontaneously
cross the blood brain barrier. Such nanobodies not only gained
access to the brain but were even found to penetrate cells and
bind to intracellular proteins. In a mouse study, the nanobody E9
(pI = 9.4) directed against glial fibrillary acidic protein (GFAP)
crossed the BBB after injection via the tail vein and was able
to bind to intracellularly expressed GFAP in astrocytes. Con-
jugation of fluorescent proteins to nanobody E9 (generating a
“fluobody”) allowed in vivo labeling of astrocytes, however, only
if the basic pI was preserved. One possible limitation of this
approach is that fairly large amounts (2 mg) of nanobody had
to be injected to obtain the desired effect. However, combining
this approach—adjusting the pI to a basic level—with other
approaches could possibly show beneficial effects. Indeed, the FC5
nanobody described above also has a basic pI (9.2) which might
contribute to or facility transcytosis into the brain parenchyma
FIGURE 2 | Delivery of nanobodies to the brain. The blood-brain-barrier
(BBB) hampers the delivery of intravenously injected nanobodies (VHH) to the
brain. To overcome this, diverse strategies are being developed: (1) Nanobody
FC5, binding to a putative α(2,3)-sialoglycoprotein receptor, can potentially be
used as shuttling-nanobody to deliver other therapeutic proteins e.g.,
nanobodies to the brain. (2) Apolipoprotein E (ApoE) binds to low density
lipoprotein receptor-related protein 1 (LRP1) inducing transcytosis, which can
be exploited as shuttle for therapeutic nanobodies. (3) In a similare fashion,
other receptors triggering transcytosis across the BBB such as the transferrin
receptor (TrfR) could be targeted for the transfer of therapeutic nanobodies.
(4) Finally, shifting the isoelectric point (pI) of therapeutic nanobodies to a
basic level facilitates crossing of the BBB by these nanobodies.
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(Farrington and Sisk, 2013). Further studies are needed to deter-
mine whether therapeutic nanobodies against inflammatory tar-
get proteins can be shuttled to the brain, e.g., by fusion to FC5 and
by adjusting their pI with the aim of treating neuroinflammatory
disease.
IMPLICATION OF NANOBODIES TO TREAT ACUTE BRAIN
INFLAMMATION
After acute brain damage, e.g., ischemic stroke or trauma, the
release of danger associated molecular pattern (DAMPs) from
necrotic cells activates resident microglia, leading to the pro-
duction of proinflammatory mediators such as cytokines and
chemokines attracting other immune cells (Amantea et al., 2009;
Iadecola and Anrather, 2011). Preventing local inflammation
could be a means to prevent further loss of brain tissue. High
mobility group box 1 (HMGB1) and nucleotide DAMPs such
as adenosinetriphosphate (ATP) are released during cerebral
ischemia (Magnus et al., 2012). Antibody-mediated neutraliza-
tion of HMGB1 or antagonism of its receptor (receptor for
advanced glycation end products, RAGE) markedly reduced the
infarct size in a mouse ischemia/reperfusion model middle cere-
bral artery occlusion (MCAO; Muhammad et al., 2008). The ATP
receptor P2X7, which mediates inflammasome formation and cell
death (Bartlett et al., 2014), was antagonized with small molecule
inhibitors in a mouse model of transient focal ischemia, again
resulting in a reduction of infarct size (Arbeloa et al., 2012).
Both pathways, HMGB1/RAGE and ATP/P2X7, display promis-
ing targets for nanobody-mediated antagonism. However, release
of DAMPs occurs shortly after the ischemic insult and before
the breakdown of the BBB (Muhammad et al., 2008; Cisneros-
Mejorado et al., 2014), requiring the generation of nanobodies
that are able to cross the BBB applying the strategies described
above. Currently, nanobodies directed against the P2X7 receptor
are under development (Laeremans et al., 2010).
An approach to control ischemia-related brain inflammation
is to prevent migration of immune cells to the penumbra of
ischemic lesions. Two independent studies demonstrated that
blockade of the CXCL12/CXCR4 axis improved the functional
outcome after stroke by attenuating post-ischemic inflammation
(Huang et al., 2013; Ruscher et al., 2013). CXCL12-CXCR4 block-
ade was conducted using the small molecule inhibitor AMD3100.
Since nanobodies against CXCL12 and CXCR4 have been gen-
erated (Jähnichen et al., 2010; Maussang et al., 2013), it may
be worthwhile to evaluate their potential in ischemia/reperfusion
animal models. To restrict the blockade of CXCR4 to infiltrating
proinflammatory cells one could apply the “activity-by-targeting”
strategy described above for IFNα2-guiding nanobodies. This
could be useful in order to allow the CXCR4-dependend migra-
tion of cells important for brain recovery after stroke such as
mesenchymal stem cells (Tsai et al., 2011). Furthermore, blockade
of other chemokine receptors such as CXCR1 and CXCR2 by
small molecule inhibitor Reparixin also reduces infiltration of
proinflammatory neutrophiles and improves the motoric recov-
ery after stroke (Sousa et al., 2013). Therefore, generation and
application of nanobodies directed against CXCR1 and CXCR2
may represent one further strategy to ameliorate consequences of
cerebral ischemia and beyond.
CONCLUSIONS
Nanobodies have been shown to be versatile and efficient bio-
logicals suitable for therapy of inflammatory diseases. Due to
their unique structure, nanobodies have the potential to modulate
the function of cell surface and secreted proteins in an agonistic
or antagonistic fashion. They can be genetically engineered
to extend their half-life in vivo and, shown in a proof-of-
concept study, to serve as shuttles for the delivery of thera-
peutic agents across the BBB. Future studies will have to show
whether this strategy could also be applied to deliver therapeu-
tic nanobodies to the brain to ameliorate the consequences of
neuroinflammation.
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